Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: A randomised controlled trial

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 2, 2012, Pages 169-177

  Dahl, Ronald ^a   Titlestad, Ingrid ^b   Lindqvist, Ari ^c   Wielders, Pascal ^d   Wray, Heather ^e   Wang, Millie ^e   Samuelsson, Viktoria ^f   Mo, John ^f   Holt, Alison ^e  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d CATHARINA HOSPITAL   (Netherlands)

^e ASTRAZENECA   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

Biomarkers; COPD; Desmosine; Lymphocytes; Matrix metalloproteinases

Indexed keywords

AZD 1236; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; CORTICOSTEROID; DESMOSINE; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; METALLOPROTEINASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL COLLAGENASE; PLACEBO; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; EOSINOPHIL; EPITHELIUM CELL; FEMALE; HUMAN; LYMPHOCYTE; LYMPHOCYTE COUNT; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NEUTROPHIL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPUTUM; SPUTUM LEVEL; SYMPTOM; URINALYSIS; VERTIGO;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; DESMOSINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84862783123     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.12.011     Document Type: Article

References (39)

1. Stockley R.A. Biomarkers in COPD: time for a deep breath. Thorax 2007, 62:657-660.
2. Barnes P.J., Stockley R.A. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005, 25:1084-1106.
3. Sevenoaks M.J., Stockley R.A. Chronic obstructive pulmonary disease, inflammation and co-morbidity-a common inflammatory phenotype?. Respir Res 2006, 7:70.
4. Karadag F., Karul A.B., Cildag O., Yilmaz M., Ozcan H. Biomarkers of systemic inflammation in stable and exacerbation phases of COPD. Lung 2008, 186:403-409.
5. Gan W., Man S., Senthilselvan A., Sin D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004, 59:574-580.
6. Sin D.D., Man S.F. Biomarkers in COPD: are we there yet?. Chest 2008, 133:1296-1298.
7. Watz H., Waschki B., Kirsten A., Müller K.-C., Kretschmar G., Meyer T., et al. The metabolic syndrome in patients with chronic Bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009, 136:1039-1046.
8. Belvisi M.G., Bottomley K.M. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs?. Inflamm Res 2003, 52:95-100.
9. Churg A., Wang R., Wang X., Onnervik P.O., Thim K., Wright J.L. Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs. Thorax 2007, 62:706-713.
10. Cazzola M., MacNee W., Martinez F.J., Rabe K.F., Franciosi L.G., Barnes P.J., et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-469.
11. Maclay J.D., Rabinovich R.A., MacNee W. Update in chronic obstructive pulmonary disease 2008. Am J Respir Crit Care Med 2009, 179:533-541.
12. Demedts I.K., Morel-Montero A., Lebecque S., Pacheco Y., Cataldo D., Joos G.F., et al. Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax 2006, 61:196-201.
13. Lagente V., Manoury B., Nenan S., Le Quement C., Martin-Chouly C., Boichot E. Role of matrix metalloproteinases in the development of airway inflammation and remodeling. Braz J Med Biol Res 2005, 38:1521-1530.
14. Churg A., Wang R.D., Tai H., Wang X., Xie C., Dai J., et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. Am J Respir Crit Care Med 2003, 167:1083-1089.
15. Elkington P.T., Friedland J.S. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006, 61:259-266.
16. Mercer P.F., Shute J.K., Bhowmik A., Donaldson G.C., Wedzicha J.A., Warner J.A. MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation. Bio Med Central Respir Res 2005, 6:151.
17. Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003, 22:672-688.
18. Data on file 2010, AstraZeneca.
19. Ma S., Lin Y.Y., Tartell L., Turino G.M. The effect of tiotropium therapy on markers of elastin degradation in COPD. Respir Res 2009, 25:12.
20. Gottlieb D.J., Stone P.J., Sparrow D., Gale M., Weiss S., Snider G., et al. Urinary desmosine excretion in smokers with and without rapid decline of lung function: the normative aging study. Am J Respir Crit Care Med 1996, 154:1290-1295.
21. Black P.N., Ching P.S.T., Beaumont B., Ranasinghe S., Taylor G., Merrilees M.J. Changes in elastic fibres in the small airways and alveoli in COPD. Eur Respir J 2008, 31:998-1004.
22. Viglio S., Iadarola P., Lupi A., Trisolini R., Tinelli C., Balbi B., et al. MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients. Eur Respir J 2000, 15:1039-1045.
23. Peterson J.T. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res 2006, 69:677-687.
24. Magnussen H., Watz H., Kirsten A., Wang M., Wray H., Samuelsson V., et al. Safety, tolerability and efficacy of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled trial. Pulm Pharmacol Ther 2010.
25. Luisetti M., Ma S., Iadarola P., Stone P.J., Viglio S., Casado B., et al. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J 2008, 32:1146-1157.
26. Gan W.Q., Man S.F., Sin D.D. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 2005, 5:3.
27. Bozinovski S., Hutchinson A., Thompson M., Macgregor L., Black J., Giannakis E., et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008, 177:269-278.
28. van der Molen T., Willemse B.W., Schokker S., ten Hacken N.H., Postma D.S., Juniper E.F. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003, 1:13.
29. Barnes P.J., Chowdhury B., Kharitonov S.A., Magnussen H., Page C.P., Postma D., et al. Pulmonary perspective. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 174:6-14.
30. Lindberg C.A., Engström G., Gerhardsson de Verdier M., Nihlén U., Anderson M., Forsman-Semb K., et al. Total desmosines in plasma and urine correlate with lung function. ERJ Express 2011.
31. Fregonese L., Fumagalli M., Ferrari F., Luisetti M., Stolk J., Belloni P., et al. [Poster board #D48] R667, a retinoid gamma receptor agonist, reduces plasma elastin breakdown products in alpha-antitrypsin deficient emphysema (AATDe), [Publication Page: A419] 2008, American Thoracic Society International Conference, Toronto.
32. Luisetti M., Sturani C., Sella D., Madonini E., Galavotti V., Bruno G., et al. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir J 1996, 9:1482-1486.
33. Abraham M., Shapiro S., Karni A., Weiner H.L., Miller A. Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunology 2005, 163:157-164.
34. Soriano J.B., Miravitlles M. Your racing horses will help you to quit: a lesson for COPD and alpha1-antitrypsin deficiency research. Eur Respir J 2009, 33:1244-1246.
35. Dawkins P.A., Dawkins C.I., Wood A.M., Nightingale P.G., Stockley J.A., Stockley R.A. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency. Eur Respir J 2009, 33:1244-1246.
36. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
37. Tashkin D.P., Celli B., Senn S., Burkhardt D., Kesten S., Menjoge S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359:1543-1554.
38. 1 - Time to divide and conquer?. NEJM 2008, 359:1616-1617.
39. GOLD Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease 2011.